Fundies.
English

NOVELOS THERAPEUTICS, INC.

EDGAR
CLRB Quarterly report (10-Q) · filed 2026-08-13

126 filing records in this dataset, filed from 2005-05-23 to 2026-08-13. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments
Watchlist
Cash and cash equivalents
34 million Unit_Standard_USD_h1SmMreUeES99X8_duPNKA Source
Exact value

33993982 Unit_Standard_USD_h1SmMreUeES99X8_duPNKA

Long-term debt including current maturities
330 thousand USD Source
Exact value

330222 USD

Shares outstanding
8.25 million Unit_Standard_shares_bjIS2bO41UaxZAxx56RbLQ Source
Exact value

8252108 Unit_Standard_shares_bjIS2bO41UaxZAxx56RbLQ

Company performance

Up to ten complete financial years · consolidated figures

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-13.

Financial data available through: 2025-12-31.

Coverage by financial measure
  • revenue: No compatible figures in this window
  • Operating income: 2 of 11 periods available· newest 2025-12-31
  • Net income: 2 of 11 periods available· newest 2025-12-31
  • Operating cash flow: 2 of 11 periods available· newest 2025-12-31
  • Capital expenditure: 2 of 11 periods available· newest 2025-12-31
  • Total assets: Multiple units; comparison withheld· newest 2025-12-31
  • Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
  • Current assets: Multiple units; comparison withheld· newest 2025-12-31
  • Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
  • Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
  • Long-term debt including current maturities: 1 of 11 periods available· newest 2015-12-31
  • Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

  • Net income

    +Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig 22.79 million

    Prior period

    −Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig 44.58 million

    –

    Current period

    −Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig 21.79 million

    –

    Exact inputs and evidence

    -21791037 − -44581446 = 22790409 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig

    -44581446 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -21791037 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Operating cash flow

    +Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig 24.46 million

    Prior period

    −Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig 47.58 million

    –

    Current period

    −Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig 23.12 million

    –

    Exact inputs and evidence

    -23118217 − -47583001 = 24464784 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig

    -47583001 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -23118217 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Capital expenditure

    -94.4%

    Prior period

    Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig 104,195

    –

    Current period

    Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig 5,880

    –

    Exact inputs and evidence

    5880 − 104195 = -98315 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig

    104195 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    5880 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.
Values and sources
Revenue values and source evidence
PeriodSeriesValueSource evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValueSource evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig)Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2024 2024-01-01 – 2024-12-31
−Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig 44.58 million
Exact value

Exact value: -44581446 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig

2024-01-01 – 2024-12-31: -44581446 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig 47.58 million
Exact value

Exact value: -47583001 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig

2024-01-01 – 2024-12-31: -47583001 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig 104,195
Exact value

Exact value: 104195 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig

2024-01-01 – 2024-12-31: 104195 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig 47.69 million
Calculation and evidence

-47583001 − 104195 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig

Exact free cash flow: -47687196 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2025 2025-01-01 – 2025-12-31
−Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig 21.79 million
Exact value

Exact value: -21791037 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig

2025-01-01 – 2025-12-31: -21791037 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig 23.12 million
Exact value

Exact value: -23118217 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig

2025-01-01 – 2025-12-31: -23118217 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig 5,880
Exact value

Exact value: 5880 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig

2025-01-01 – 2025-12-31: 5880 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig 23.12 million
Calculation and evidence

-23118217 − 5880 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig

Exact free cash flow: -23124097 Unit_Standard_USD_uhmcMwKXHUy9QixcvAm1Ig

Share or cite

The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

126 filings · 5,364 latest values · 5,364 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0001279704, 1279704, CLRB, NVLT, edgar:1279704, nvlt

Also known as CELLECTAR BIOSCIENCES, INC., CELLECTAR BIOSCIENCES, INC., COMMON HORIZONS INC, Cellectar Biosciences, Inc., NOVELOS THERAPEUTICS, INC.